DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas

Information source: Advantagene, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma

Intervention: AdV-tk (Biological); Valacyclovir (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Advantagene, Inc.

Official(s) and/or principal investigator(s):
E. Antonio Chiocca, MD, PhD, Principal Investigator, Affiliation: Ohio State University

Summary

This phase I study evaluated a Gene Mediated Cytotoxic Immunotherapy approach for malignant gliomas, including glioblastoma multiforme and anaplastic astrocytoma. The purpose of this study was to assess the safety and feasibility of delivering an experimental approach called GliAtak which uses AdV-tk, an adenoviral vector containing the Herpes Simplex thymidine kinase gene, plus an oral anti-herpetic prodrug, valacyclovir, in combination with standard of care radiation.

Clinical Details

Official title: A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Safety of the intervention will be evaluated based on laboratory and clinical parameters graded using CTCAEver3.

Secondary outcome:

Tumor Response

Progression-free Survival

Overall Survival

Quality of Life (QOL)

Detailed description: This study was designed to include patients with newly diagnosed unresectable (Arm A) and resectable (Arm B) malignant glioma. Three dose levels of AdV-tk were evaluated with a fixed dose level of valacyclovir prodrug. AdV-tk was delivered to tumor cells by stereotactic injection into the tumor at the time of biopsy (Arm A) or injection into the tumor bed following resection (Arm B). Oral valacyclovir began 1-3 days after the AdV-tk injection and continued for 14 days. Standard radiation therapy began 3-7 days following the AdV-tk injection to maximize synergy with radiation. Standard temozolomide could be administered after completion of valacyclovir.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Presumed malignant glioma based on clinical and radiologic evaluation (pathologic

confirmation of malignant glioma must be made at the time of stereotactic biopsy or resection prior to AdV-tk injection; if this is not possible, the injection will not be performed and the subject will no longer be eligible for the study).

- Tumor must be accessible for injection and must not be located in the brainstem,

midbrain, contained within the ventricular system, or located in an infratentorial location.

- Patients must be planning to undergo standard radiation therapy.

- Patients must be 18 years of age or older.

- Performance status must be KPS > or equal to 70.

- Patients must have SGOT (AST) < 3x upper limit of normal.

- Patients must have serum creatinine < 2mg/dl and calculated creatinine clearance

>10ml/min.

- Patients must have platelets > 100,000/mm3 and WBC > 3000/mm3.

- Patients of reproductive age must agree to use a medically accepted form of birth

control while on the study.

- Patients must give study specific informed consent prior to enrollment.

- Patients must be able to tolerate MRI scan procedure

Exclusion Criteria:

- Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection

but not to exclude patients with a distant history of resolved hepatitis A infection.

- Patients on immunosuppressive drugs (with exception of corticosteroid)

- Known HIV+ patients.

- Patients with acute infections (viral, bacterial or fungal infections requiring

therapy).

- Pregnant or breast feeding patients. Female patients of childbearing age must have

negative serum or urine pregnancy test within 1 week of beginning therapy.

- Evidence of metastatic disease or other malignancy (except squamous or basal cell

skin cancers).

- Prior radiation therapy to the brain or prior treatment for brain tumor (except prior

biopsy or subtotal resection).

- Other serious co-morbid illness or compromised organ function.

- Patients may not receive temozolomide until valacyclovir completed and may not

receive other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from study entry until tumor progression).

Locations and Contacts

The Ohio State University Medical Center, Dept Neurosurgery, Columbus, Ohio 43210, United States

The Methodist Hosptial, Houston, Texas 77030, United States

Additional Information

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma

Starting date: November 2005
Last updated: March 10, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017